Sugi Predict

Sugi Predict / Compounds / SCHEMBL1309909

SCHEMBL1309909

SCHEMBL1309909

CC(C)(C)OC(=O)N[C@H](Cc1ccc(Cl)cc1)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PPARA Q07869 7/20 0.65
▸ PPARG P37231 6/20 0.65
▸ ACE P12821 1/20 0.62
▸ ITGB3 P05106 2/20 0.62
▸ ITGA2B P08514 2/20 0.62
▸ CTSS P25774 6/20 0.56
▸ CTSK P43235 5/20 0.56
▸ CTSL P07711 2/20 0.55
▸ CTSB P07858 1/20 0.55
▸ ITGA4 P13612 1/20 0.53
▸ ITGB7 P26010 1/20 0.53
▸ PTPN1 P18031 2/20 0.53
▸ PPARD Q03181 2/20 0.52
▸ ITGB1 P05556 1/20 0.52
▸ ITGAV P06756 1/20 0.52
▸ ITGB5 P18084 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL181848 1.00 PPARA (0.65) PPARAPPARGACEITGB3ITGA2B
SCHEMBL181849 1.00 PPARA (0.65) PPARAPPARGACEITGB3ITGA2B
SCHEMBL3722240 0.96 PPARA (0.61) PPARAPPARGACEITGB3ITGA2B
SCHEMBL22009950 0.96 PPARA (0.61) PPARAPPARGACEITGB3ITGA2B
SCHEMBL3722245 0.96 PPARA (0.61) PPARAPPARGACEITGB3ITGA2B
SCHEMBL2290585 0.94 ITGB3 (0.62) PPARAPPARGACEITGB3ITGA2B
SCHEMBL2290589 0.94 ITGB3 (0.62) PPARAPPARGACEITGB3ITGA2B
SCHEMBL2287582 0.91 ITGB3 (0.59) PPARAPPARGACEITGB3ITGA2B
SCHEMBL2287578 0.91 ITGB3 (0.59) PPARAPPARGACEITGB3ITGA2B
SCHEMBL7481627 0.89 PPARG (0.59) PPARAPPARGACEITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-104910046-B Phenylacetylene derivative with double chiral carbon atoms on pendant group and preparation method and application thereof 哈尔滨工程大学 2017-05-24 — — CN claimed
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME NEW YORK UNIVERSITY (US) 2026-01-01 — — US disclosed
US-12459894-B2 Orally active melanocortin receptor-4 compounds PALATIN TECHNOLOGIES, INC. (US) 2025-11-04 — — US disclosed
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2025-09-02 — — US disclosed
US-12371461-B2 Nemo coiled coil mimics and methods of using same NEW YORK UNIVERSITY (US) 2025-07-29 — — US disclosed
CN-120192379-A Marine cyclic peptide and synthesis method and application thereof 内蒙古大学 2025-06-24 — — CN disclosed
EP-3303367-B1 STABILIZED MINIMAL COILED-COIL MIMETICS UNIV NEW YORK (US) 2025-06-18 — — EP disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
US-20240190930-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME UNIV NEW YORK (US) 2024-06-13 — — US disclosed
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2024-04-30 — — US disclosed
EP-0820453-A4 THROMBIN INHIBITORS MERCK & CO INC (US) 2001-08-29 — — EP disclosed
EP-1085869-A1 SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS Merck & Co., Inc. (US) 2001-03-28 — — EP disclosed
WO-1999064002-A1 SPIROPIPERIDINE DERIVATIVES AS MELANOCORTIN RECEPTOR AGONISTS MERCK & CO., INC. (US) 1999-12-16 — — WO disclosed
EP-0820453-A1 THROMBIN INHIBITORS Merck & Co., Inc. (US) 1998-01-28 — — EP disclosed
WO-1996031504-A1 THROMBIN INHIBITORS MERCK & CO., INC. (US) 1996-10-10 — — WO disclosed
US-5216124-A Analgesics G. D. SEARLE & CO. (US) 1993-06-01 — — US disclosed
US-5169833-A Analgesics G. D. SEARLE & CO. (US) 1992-12-08 — — US disclosed
WO-1991008759-A1 ALKYL SUBSTITUTED CYCLIC PENICILLANIC ACID PENTAPAPTIDES G.D. SEARLE & CO. (US) 1991-06-27 — — WO disclosed
WO-1991009051-A1 SUBSTITUTED CYCLIC PENICILLANIC ACID TETRAPEPTIDES G.D. SEARLE & CO. (US) 1991-06-27 — — WO disclosed
US-4504414-A Synthetic pyridyl-alanyl decapeptides having antiovulatory activity BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 1985-03-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 PPARA 3678/4885PPARG 2613/4885ACE 1597/4885
US-12459894-B2 Orally active melanocortin receptor-4 compounds MC4R, MC1R, MC3R PPARA 1521/4885PPARG 1844/4885ACE 2264/4885
US-12371461-B2 Nemo coiled coil mimics and methods of using same COIL, CALCOCO2, NCAPH PPARA 4497/4885PPARG 4002/4885ACE 4652/4885
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 PPARA 3678/4885PPARG 2613/4885ACE 1597/4885
US-20260001924-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME DDX21, PHAX, RBX1 PPARA 3778/4885PPARG 3003/4885ACE 4863/4885
US-20240190930-A1 NEMO COILED COIL MIMICS AND METHODS OF USING SAME COIL, CALCOCO2, NCAPH PPARA 4462/4885PPARG 4013/4885ACE 4653/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.